In a recent phase 3 clinical trial the combination of nivolumab plus ipilimumab was assessed as an adjuvant treatment for people with localised kidney cancer. Adjuvant treatment is treatment that is given after surgery to prevent the cancer from coming back. In this study, the combination of nivolumab plus ipilimumab was given to people who had had a full or partial removal of their kidney and who were at moderate or high risk of their cancer returning.
The combination was compared to people who were given placebo (an infusion without any active medicines). However, the results showed that treatment with nivolumab plus ipilimumab was no better than placebo at preventing the cancer from coming back and did not improve survival compared to placebo. The safety of nivolumab plus ipilimumab was similar to that reported in other clinical trials.
The study is continuing with nivolumab alone compared to placebo.